Drugs / KESONOTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06926075 | Nov 2025 → Oct 2027 expected | breast cancer, glioblastoma, lung cancer, malignant pancreatic neoplasm +3 | Filamon LTD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KESONOTIDE | “This clinical trial is an adaptive phase I/II study of KESONOTIDE™, a novel hGIIA-vimentin inhibitor in participants with solid tumours.” NCT06926075 ↗ |
| Action | Inhibit | “novel vimentin inhibitor” NCT06926075 ↗ |
| Route | Oral | “KESONOTIDE™ will be orally administered.” NCT06926075 ↗ |